Fast Melt Cocoa Butter Tablet: Effect of Waxes, Starch, and PEG 6000 on Physical Properties of the Preparation

被引:3
作者
Liew, Kai Bin [1 ]
Ming, Long Chiau [2 ]
Goh, Bey-Hing [3 ,4 ]
Peh, Kok Khiang [5 ]
机构
[1] Univ Cyberjaya, Fac Pharm, Cyberjaya 63000, Malaysia
[2] Univ Brunei Darussalam, PAP Rashidah Saadatul Bolkiah Inst Hlth Sci, BE-1410 Gadong, Brunei
[3] Monash Univ Malaysia, Sch Pharm, Biofunct Mol Exploratory Res Grp, Bandar Sunway 47500, Malaysia
[4] Zhejiang Univ, Coll Pharmaceut Sci, Hangzhou 310058, Peoples R China
[5] Univ Sains Malaysia, Sch Pharmaceut Sci, Minden 11800, Malaysia
来源
MOLECULES | 2022年 / 27卷 / 10期
关键词
fast melt tablet; cocoa butter; dapoxetine; starch; PEG; 6000; wax; ORALLY DISINTEGRATING TABLETS; SOLID DISPERSIONS; DISSOLUTION; FORMULATION;
D O I
10.3390/molecules27103128
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
A fast melt tablet (FMT) is well regarded as an alternative delivery system that might help resolve a patient's non-compliance issue. The main objective of this study was to develop a cocoa butter-based FMT. Additives, namely 5-15% of PEG 6000, beeswax, paraffin wax, and corn starch, were incorporated into the cocoa butter-based FMT to study the effects of these additives with the physical characteristic of a cocoa butter FMT. An optimum-based formulation was chosen according to the desired hardness and disintegration time and the taste masking property achieved with the model drug-dapoxetine. The analysis demonstrated that incorporating beeswax (15%) and paraffin wax (15%) could prolong the disintegration time by at least two-fold. On the contrary, the presence of corn starch was found to cause an increase in the hardness and reduction of the disintegration time. The disintegration mechanism might be presumed due to the synergistic effect of starch swelling and cocoa butter melting. The hardness value and in vitro disintegration time of the optimum formulation were recorded at 2.93 +/- 0.22 kg and 151.67 +/- 6.98 s. In terms of dissolution, 80% of dapoxetine was released within 30 min and the dissolution profile was comparable to the innovator product. The formulation was palatable and stable for at least 1 year. The exposure of the FMT formulation at 30 degrees C for 12 months was reported to be stable. Along with the sound palatability profile and high drug load capacity, the current formulation possesses the desired characteristics to be scaled up and marketed.
引用
收藏
页数:15
相关论文
共 43 条
  • [1] Formulation of a fast-dissolving ketoprofen tablet using freeze-drying in blisters technique
    Ahmed, IS
    Nafadi, MM
    Fatahalla, FA
    [J]. DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2006, 32 (04) : 437 - 442
  • [2] Allen L.V., 1994, U.S. Patent., Patent No. [No. 5,807,576, 5807576]
  • [3] Allen L.V., 1996, U.S. Patent., Patent No. [No. 5,587,180, 5587180]
  • [4] Allen L.V., 1994, U.S. Patent, Patent No. [No. 5,635,210, 5635210]
  • [5] Baheti A., 2016, J. Excipients Food Chem, V1, P1135
  • [6] Comparison of physicochemical properties of suppositories containing starch hydrolysates
    Belniak, Piotr
    Swiader, Katarzyna
    Szumilo, Michal
    Hyla, Aleksandra
    Poleszak, Ewa
    [J]. SAUDI PHARMACEUTICAL JOURNAL, 2017, 25 (03) : 365 - 369
  • [7] Bhasin R K., 2011, IGJPS, V1, P328, DOI DOI 10.35652/IGJPS.2011.33
  • [8] Investigation on the effect of polymer and starch on the tablet properties of lyophilized orally disintegrating tablet
    Bin Liew, Kai
    Peh, Kok Khiang
    [J]. ARCHIVES OF PHARMACAL RESEARCH, 2021, 44 (08) : 817 - 826
  • [9] Taste-masked and affordable donepezil hydrochloride orally disintegrating tablet as promising solution for non-compliance in Alzheimer's disease patients
    Bin Liew, Kai
    Tan, Yvonne Tze Fung
    Peh, Kok Khiang
    [J]. DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2015, 41 (04) : 583 - 593
  • [10] Evaluation of co-processed excipients used for direct compression of orally disintegrating tablets (ODT) using novel disintegration apparatus
    Brniak, Witold
    Jachowicz, Renata
    Krupa, Anna
    Skorka, Tomasz
    Niwinski, Krzysztof
    [J]. PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY, 2013, 18 (02) : 464 - 474